AZ’s Susan Galbraith On What’s Next In The Cancer Pipeline
Executive Summary
One of the architects of AstraZeneca’s burgeoning cancer portfolio, oncology R&D head Susan Galbraith is making sure the firm does not rest on its laurels. She talked to In Vivo about what’s coming next from the UK major’s cancer pipeline.
You may also be interested in...
Innate Lead Candidate Fails In Head And Neck Cancer But Partner AZ Offers Hope In NSCLC
Innate’s lead candidate has reached the end of the road in head and neck carcinoma after a disappointing interim Phase III trial analysis but hope remains that a combination with partner AstraZeneca's Imfinzi could succeed elsewhere.
AstraZeneca’s Susan Galbraith To Lead Its Entire Cancer R&D
After more that 10 years at the firm, Susan Galbraith has taken on an expanded role heading up oncology R&D at AstraZeneca.
DESTINY Calls For Daiichi Sankyo/AZ’s Enhertu In Other Indications
Daiichi Sankyo and AstraZeneca’s ambitions to expand the use of their HER-2 targeted antibody-drug conjugate product beyond breast cancer are looking realizable on the back of new results presented at ASCO, but toxicities remain an issue.